Tobam Reduces Stock Position in Humana Inc. $HUM

Tobam cut its holdings in Humana Inc. (NYSE:HUM) by 36.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,910 shares of the insurance provider’s stock after selling 6,754 shares during the period. Tobam’s holdings in Humana were worth $3,099,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Massachusetts Financial Services Co. MA raised its position in shares of Humana by 273.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider’s stock worth $907,541,000 after acquiring an additional 2,553,509 shares in the last quarter. Norges Bank purchased a new position in Humana in the second quarter valued at approximately $397,079,000. Bank of New York Mellon Corp lifted its position in shares of Humana by 161.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,717,767 shares of the insurance provider’s stock worth $446,911,000 after buying an additional 1,060,767 shares during the last quarter. Dodge & Cox boosted its holdings in shares of Humana by 5.6% in the 2nd quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock valued at $2,775,562,000 after buying an additional 597,705 shares in the last quarter. Finally, 8 Knots Management LLC boosted its holdings in shares of Humana by 671.0% in the 2nd quarter. 8 Knots Management LLC now owns 441,623 shares of the insurance provider’s stock valued at $107,968,000 after buying an additional 384,345 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HUM. Zacks Research cut shares of Humana from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 1st. TD Cowen cut their target price on Humana from $260.00 to $173.00 and set a “hold” rating on the stock in a research report on Friday. Weiss Ratings reissued a “sell (d+)” rating on shares of Humana in a research report on Thursday, January 22nd. Guggenheim cut their price target on Humana from $312.00 to $252.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, JPMorgan Chase & Co. reduced their price objective on Humana from $274.00 to $180.00 and set a “neutral” rating for the company in a research note on Friday. Seven research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, Humana currently has a consensus rating of “Hold” and an average price target of $238.29.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Stock Performance

NYSE HUM opened at $183.92 on Monday. The firm has a market cap of $22.12 billion, a P/E ratio of 18.73, a P/E/G ratio of 1.96 and a beta of 0.44. Humana Inc. has a 52-week low of $169.61 and a 52-week high of $315.35. The business’s 50-day moving average price is $244.65 and its 200 day moving average price is $261.02. The company has a quick ratio of 2.02, a current ratio of 2.00 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company had revenue of $32.64 billion during the quarter, compared to analysts’ expectations of $32.08 billion. During the same period last year, the firm earned ($2.16) EPS. The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, equities research analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.